ADVB$6.19+0.00%

Fair $6.19+0.0%

ADVB

Advanced Biomed Inc.

Healthcare / Diagnostics & ResearchNasdaqCM

$6.19

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $6.19Fund rank 31/100 · Data gapFallback financials|

SA 0/F

F-Score: 1/9

Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 26% · confianza 25%

FCF escenarios

weak_data · normalized FCF $-4.0M · quality 56.0/100

Data gap 31/100

Bear 5Yn/dn/d

Base 5Yn/dn/d

Bull 5Yn/dn/d

Return 0/100Downside 20/100Model quality 60/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

0/100

Piotroski

1/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

8/100

SEC 0%

Latest source: unknownPeriods: 2Warnings: 1unknown: 2

No SEC-backed annual rows; valuation uses fallback financial data. Limited financial history; valuation confidence should be treated as provisional. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -93.7%, below the 5% threshold

Thesis & Journal · ADVBLocal privado en este navegador · Advanced Biomed Inc.

Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Tesis central

Bull caseBase caseBear case

CatalizadoresRiesgos

Kill criteria

Mi valoración / targetReview date

Sin guardar todavía.

Market Cap

$10M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-93.7%

↓

Gross Margin

N/A

•

Debt/Equity

N/A

•

No hay histórico de precio usable para pintar el gráfico TradingView.

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2024–2025 · 1 años de histórico normalizado

Revenue CAGR

—

FCF CAGR

—

FCF margin

—

FCF / Net income

1.80x

Latest source

Provider fallback

Margin decomposition

Último año: revenue — · net income $-3.3M · FCF $-5.9M

2024-FY → 2025-FY

Gross margin

—— pts

Operating margin

—— pts

Net margin

—— pts

FCF margin

—— pts

Metric	TTM	2025	2024
Income Statement
Net Income	$-3.3M	$-3.3M	$-2.8M
EPS	-0.16	-0.16	-0.14
Cash Flow
Free Cash Flow	$-5.9M	$-5.9M	$-2.2M
Returns
ROE	-93.7%	-93.7%	-167.3%
Growth & Yield
EPS Growth	-14.3%	-14.3%	—

Returns (%)